Double-blind, multi-centre parallel trial of ketoprofen and ibuprofen in the treatment of rheumatoid arthritis.
A double-blind parallel multi-centre study of 102 patients with rheumatoid arthritis (RA) was performed, comparing ibuprofen (1200-2400 mg daily) and ketoprofen (150-300 mg daily) a new non-steroidal, anti-inflammatory agent, over a three month period. Ketoprofen was well tolerated and shown to have comparable efficacy with ibuprofen. Longterm efficacy and tolerance studies are indicated.